Allovectin-7

Allovectin-7

A gene-based product containing HLA-B7, an antigen responsible for strong immune responses such as transplant organ rejection; Allovectin-7 injection into cancer might theoretically trigger the body's immune system to recognise the cancer as foreign and destroy it.

It was granted orphan drug status for the management of melanoma and is in Phase-3 trials for managing advanced melanoma.
References in periodicals archive ?
Table 6-8: Potential Market Size of Allovectin-7 in the US and EU (Million US$)
Vical) today announced the start of phase III of their clinical trial of Allovectin-7 -a gene therapy treatment drug for progressive melanoma patients.
MINNEAPOLIS -- Interim results from a phase II trial indicate that Allovectin-7 is an active, well-tolerated treatment for advanced metastatic melanoma patients, Dr.
The new patent covers a range of applications of the company's core DNA delivery technology, including cationic lipid-formulated, gene-based immunotherapeutics such as Vical's clinical-stage Allovectin-7 treatment for melanoma, cationic lipid-formulated DNA vaccines such as Vical's developmental anthrax vaccine, and similar pharmaceutical products under development by others.
Ten years ago, Allovectin-7 was in a similar position, but it failed to meet its efficacy endpoint in phase III.
Tokyo, Japan, May 30, 2006 - (JCN) - AnGes MG announced on May 30 that it has signed a collaboration agreement with US bio venture company Vical for Allovectin-7, Vical's proprietary immunotherapeutic for malignant melanoma.
Vical's two lead product candidates, Allovectin-7 and Leuvectin, both involve direct injection of genetic material into tumors or surrounding tissue using lipids to facilitate delivery.
Collategene by AnGes MG, Cardium Therapeutics' Generx, and Vical Incorporation's Allovectin-7 are in development for a wide range of cancer indications, and are expected to compete in the oncology therapeutics market as the market acceptance of gene therapy improves over time.
Vical Inks Agreement with Abic for Allovectin-7 Immunotherapeutic II-29
CHICAGO -- University of Illinois at Chicago researchers are participating in a multi-center research trial to evaluate the safety and effectiveness of Allovectin-7, an investigational treatment for advanced melanoma.